



Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 28, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 28, 2023-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Swarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET.

Interested parties can access the live webcast [here](#). An archived copy of the webcast will be available on the [events section](#) of the company's [investor relations website](#) for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS). To learn more, visit www.sprucebio.com and follow us on Twitter/X @[Spruce_Bio](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20230828696222/en/>

Media Contact

Will Zasadny
Evoke Canale
(619) 961-8848
will.zasadny@evokegroup.com
media@sprucebio.com

Investors

Samir Gharib
President and CFO
Spruce Biosciences
investors@sprucebio.com

Source: Spruce Biosciences